These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 28345935

  • 1. Targeting Self-Binding Peptides as a Novel Strategy To Regulate Protein Activity and Function: A Case Study on the Proto-oncogene Tyrosine Protein Kinase c-Src.
    Bai Z, Hou S, Zhang S, Li Z, Zhou P.
    J Chem Inf Model; 2017 Apr 24; 57(4):835-845. PubMed ID: 28345935
    [Abstract] [Full Text] [Related]

  • 2. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
    Zhou P, Hou S, Bai Z, Li Z, Wang H, Chen Z, Meng Y.
    Artif Cells Nanomed Biotechnol; 2018 Sep 24; 46(6):1122-1131. PubMed ID: 28754059
    [Abstract] [Full Text] [Related]

  • 3. Why the first self-binding peptide of human c-Src kinase does not contain class II motif but can bind to its cognate Src homology 3 domain in class II mode?
    Zhou P, Yan F, Miao Q, Chen Z, Wang H.
    J Biomol Struct Dyn; 2021 Jan 24; 39(1):310-318. PubMed ID: 31872783
    [Abstract] [Full Text] [Related]

  • 4. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo.
    Lerner EC, Smithgall TE.
    Nat Struct Biol; 2002 May 24; 9(5):365-9. PubMed ID: 11976726
    [Abstract] [Full Text] [Related]

  • 5. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
    Bradshaw JM, Mitaxov V, Waksman G.
    J Mol Biol; 1999 Nov 05; 293(4):971-85. PubMed ID: 10543978
    [Abstract] [Full Text] [Related]

  • 6. Conformational basis for SH2-Tyr(P)527 binding in Src inactivation.
    Ayrapetov MK, Wang YH, Lin X, Gu X, Parang K, Sun G.
    J Biol Chem; 2006 Aug 18; 281(33):23776-84. PubMed ID: 16790421
    [Abstract] [Full Text] [Related]

  • 7. Binding, domain orientation, and dynamics of the Lck SH3-SH2 domain pair and comparison with other Src-family kinases.
    Hofmann G, Schweimer K, Kiessling A, Hofinger E, Bauer F, Hoffmann S, Rösch P, Campbell ID, Werner JM, Sticht H.
    Biochemistry; 2005 Oct 04; 44(39):13043-50. PubMed ID: 16185072
    [Abstract] [Full Text] [Related]

  • 8. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains.
    Chalupny NJ, Aruffo A, Esselstyn JM, Chan PY, Bajorath J, Blake J, Gilliland LK, Ledbetter JA, Tepper MA.
    Eur J Immunol; 1995 Oct 04; 25(10):2978-84. PubMed ID: 7589101
    [Abstract] [Full Text] [Related]

  • 9. Yeast two-hybrid in vivo association of the Src kinase Lyn with the proto-oncogene product Cbl but not with the p85 subunit of PI 3-kinase.
    Dombrosky-Ferlan PM, Corey SJ.
    Oncogene; 1997 May 01; 14(17):2019-24. PubMed ID: 9160881
    [Abstract] [Full Text] [Related]

  • 10. Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: the intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated.
    Boerner RJ, Kassel DB, Barker SC, Ellis B, DeLacy P, Knight WB.
    Biochemistry; 1996 Jul 23; 35(29):9519-25. PubMed ID: 8755732
    [Abstract] [Full Text] [Related]

  • 11. Src protein-tyrosine kinase structure and regulation.
    Roskoski R.
    Biochem Biophys Res Commun; 2004 Nov 26; 324(4):1155-64. PubMed ID: 15504335
    [Abstract] [Full Text] [Related]

  • 12. Alternative modes of tyrosyl phosphopeptide binding to a Src family SH2 domain: implications for regulation of tyrosine kinase activity.
    Ladbury JE, Hensmann M, Panayotou G, Campbell ID.
    Biochemistry; 1996 Aug 27; 35(34):11062-9. PubMed ID: 8780508
    [Abstract] [Full Text] [Related]

  • 13. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.
    Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, Miller WT.
    Nature; 1997 Feb 13; 385(6617):650-3. PubMed ID: 9024665
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting the SH3 domain of human osteoclast-stimulating factor with rationally designed peptoid inhibitors.
    Han S, Liu Q, Wang F, Yuan Z.
    J Pept Sci; 2016 Aug 13; 22(8):533-9. PubMed ID: 27443979
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel mechanism of regulation of the non-receptor protein tyrosine kinase Csk: insights from NMR mapping studies and site-directed mutagenesis.
    Shekhtman A, Ghose R, Wang D, Cole PA, Cowburn D.
    J Mol Biol; 2001 Nov 16; 314(1):129-38. PubMed ID: 11724538
    [Abstract] [Full Text] [Related]

  • 19. The SH3 and SH2 domains are capable of directing specificity in protein interactions between the non-receptor tyrosine kinases cSrc and cYes.
    Summy JM, Guappone AC, Sudol M, Flynn DC.
    Oncogene; 2000 Jan 06; 19(1):155-60. PubMed ID: 10644991
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.